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Abstract
Background: Leukemias are malignant proliferative disorders of the blood forming system. Sequencing studies
demonstrate that the leukemic cell population consists of multiple clones. The genetic relationship between the
different clones, referred to as the clonal hierarchy, shows high interindividual variability. So far, the source of this
heterogeneity and its clinical relevance remain unknown. We propose a mathematical model to study the emergence
and evolution of clonal heterogeneity in acute leukemias. The model allows linking properties of leukemic clones in
terms of self-renewal and proliferation rates to the structure of the clonal hierarchy.
Results: Computer simulations imply that the self-renewal potential of the first emerging leukemic clone has a major
impact on the total number of leukemic clones and on the structure of their hierarchy. With increasing depth of the
clonal hierarchy the self-renewal of leukemic clones increases, whereas the proliferation rates do not change
significantly. The emergence of deep clonal hierarchies is a complex process that is facilitated by a cooperativity of
different mutations.
Conclusion: Comparison of patient data and simulation results suggests that the self-renewal of leukemic clones
increases with the emergence of clonal heterogeneity. The structure of the clonal hierarchy may serve as a marker for
patient prognosis.
Reviewers: This article was reviewed by Marek Kimmel, Tommaso Lorenzi and Tomasz Lipniacki.
Keywords: Acute leukemia, Heterogeneity, Clonal evolution, Mathematical modeling, Patient prognosis, Mutation,
Self-renewal, Clonal hierarchy
Background
Acute leukemias are clonal diseases of the blood form-
ing (hematopoietic) system. They lead to expansion of
malignant cells and resulting impairment of blood cell
formation. Over the last years evidence has accumulated
that many leukemia subtypes are maintained by a sub-
population of cells with stem cell-like properties [1–3].
These cells are referred to as leukemic stem cells (LSCs)
or leukemia initiating cells (LICs) and potentially trigger
relapse of the disease [4, 5]. Recent sequencing stud-
ies have confirmed that the leukemic cell population is
composed of different clones [6–8]. The size and number
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of clones follows a complex evolution over the course
of the disease [9–12]. Genetic heterogeneity of different
clones seems to result in functional differences, such as a
different engraftment potential in mice or different prolif-
eration rates [13, 14]. Nevertheless, a direct link between
genotype and cell function is still missing [13].
Genetic instability is a hallmark of solid cancers but
a relatively rare event in acute leukemias. The num-
ber of somatic mutations detected in acute leukemias is
small compared to most other cancers [15, 16]. Neverthe-
less acute leukemias show a considerable interindividual
genetic heterogeneity and a complex genetic relationship
among the different clones. The clonal architecture of
leukemias shows high interindividual variability [12], see
Fig. 1 for examples. The source of this variability is so far
unknown.
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Fig. 1 Examples of the clonal architecture detected in leukemic
patients. Each tree corresponds to one patient. The cell at the top
corresponds to the leukemic founder cell which acquires additional
mutations and gives rise to multiple leukemic clones. The examples
are taken from [12]. Reconstruction of the clonal architecture from
genetic measurements is not always unique. In case of ambiguity
only one possibility is shown in the figure
Clonal evolution in leukemias is a complex process.
Hematopoiesis is known to be a tightly regulated pro-
cess subject to several nonlinear feedback mechanisms
[17]. Leukemic cells of many patients have the potential
to interact with hematopoietic feedback signals [18, 19].
This may include leukemic cell stimulation by hematopoi-
etic factors as well as alteration of the concentration of
feedback signals by leukemic cells. Experiments further
suggest the interaction of leukemic cells with the bone
marrow microenvironment [20, 21]. Nonlinear interac-
tions between hematopoiesis and the leukemic cell expan-
sion on one hand and the limited bone marrow space on
the other may influence clonal selection [22]. The fact
that important cell parameters such as proliferation rates
or self-renewal probability cannot be measured in vivo
further limits our understanding of leukemia evolution.
Especially the following questions are so far unresolved:
• What is the source of interindividual differences of
the clonal hierarchy of leukemias?
• What is the functional difference in terms of
self-renewal and proliferation rates between cells at
the top of the hierarchy and their descendants which
have acquired additional mutations?
• How do clones that appear early during the disease
differ from clones that appear later?
• How do properties of leukemic cells present at one
point in time influence the structure of the clonal
hierarchy in the future?
• How do mutation rates influence the structure of the
clonal hierarchy?
These questions are of clinical relevance, since prop-
erties of the leukemic stem cells are important deter-
minants of disease dynamics, therapy resistance and
relapse [14, 22, 23]. Deciphering of the clonal archi-
tecture using genomic methods has become more effi-
cient and less expensive in recent years. Prediction of
patient prognosis based on genetic markers alone is
not straightforward, since leukemogenetic hits vary con-
siderably among patients and the interplay of the dif-
ferent detected mutations is complex and only par-
tially understood [24, 25]. Therefore, the question
arises if the structure of the clonal architecture pro-
vides additional insights into cell properties and patient
prognosis.
We propose a mathematical modeling approach to pro-
vide potential answers to these questions. Mathematical
models allow to systematically study the impact of cell
parameters such as mutation rates, proliferation rates
and self-renewal probability on the clonal hierarchy of
cells. Simulation of the clonal selection process provides
hints about which cell properties are linked to selective
advantage and how these properties evolve over time.
The modeling approach allows linking the position of a
clone within the hierarchy to functional properties, such
as self-renewal and proliferation rates, and to compare
it to functional properties of clones located at different
positions in the hierarchy. The structure of the clonal
architecture obtained in model simulations is compared
to experimental data from the literature and thus allows
linking observations at the level of population dynamics to
the cell function in terms of self-renewal and proliferation
rates.
Different mathematical concepts have been proposed
to model mutations. Depending on the focus of inter-
est, different approaches can be applied. Moran process
[26, 27] is used to describe populations with size that is
constant in time. Branching processes are used to describe
acquisition of mutations in growing populations. Exam-
ples include the accumulation of passenger and driver
mutations, interaction among driver mutations or accu-
mulation of mutations during DNA copying [28–31]. In
case of a large population and a continuous trait space,
diffusion [32, 33] or integral kernels [34–36] have been
used to describe the effect of mutations. A rigorous rela-
tionship between processes at the level of single cells
and limit descriptions in terms of deterministic or prob-
abilistic equations is provided in ref. [37]. Examples for
deterministic approaches to study mutations in discrete
or continuously structured population models are given
in ref. [38–40]. Computer simulations of individual-based
models and cellular automata provide a framework to
study the impact of cellular processes on the whole pop-
ulation. Examples for individual-based cancer models can
be found in ref. [41, 42].
This work is structured as follows. In the “Methods”
section, we introduce the mathematical model. In the
“Results” section, we present simulation results and their
biological interpretation. The “Discussion” section con-
cludes with a discussion of clinical implications of the
results obtained.
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We adhere to the following terminology. Clonal archi-
tecture (clonal hierarchy) is understood as the genetic
relationship between different clones. We represent the
clonal architecture as a tree. Progeny of a node has
acquired one additional mutation compared to its mother
node. As a clone we understand all genetically identical
stem and non-stem cells. A clone consisting of at least 1 %
of the total cell mass is denoted as a significant clone. The
threshold of 1 % has been chosen based on the sensitivity
of sequencing methods [43].
Methods
The model is defined as a system of nonlinear ordi-
nary differential equations describing time evolution of
hematopoietic cells and leukemic clones. Experimental
data imply that hematopoietic and leukemic cells inter-
act, e.g., through feedback signals or the bone marrow
microenvironment [18–21]. Therefore, the model takes
into account both healthy and leukemic cells. The pre-
sented model is an extension of the models of healthy
hematopoiesis [44–46] and acute leukemias [22, 23, 47].
The main novelty lies in considering a time dependent
number of leukemic clones and in tracking the structure
of the clonal hierarchies. During the course of the dis-
ease new clones arise due to mutations which are acquired
by leukemic cells. Properties of new clones are chosen
from random distributions that depend on the properties
of the cells that give rise to them. To model stochastic
extinction of clones with favorable properties, we take into
account their extinction probabilities using the theory of
branching processes. Compared to the work presented
in [40], which focuses on neutral mutations in non-stem
cells without feedback regulation or competition, we are
interested in the evolution of non-neutral stem cell muta-
tions under competitive pressure of a nonlinear feedback
mechanism. An overview of the model is provided in
Fig. 2a.
Model structure
Based on the classical understanding of the hematopoi-
etic system [48] blood cell formation is considered
as a stepwise process, with cells sequentially travers-
ing an ordered sequence of discrete maturation states
(compartments). We treat each compartment as a
“well-mixed tank” and describe its evolution using
an ordinary differential equation. The large count
of cells in the hematopoietic system justifies this
approach [48].
Since most leukemias are diseases of the white blood
cells, we only consider the white cell lineage of the healthy
hematopoietic system. The model describes the interac-
tion of the healthy cell lineage with an arbitrary number
of leukemic clones. We assume that each lineage or clone
consists of two different cell types, namely cells that are
able to divide (stem and progenitor cells) and cells that
have lost the ability to divide (mature cells or post-mitotic
leukemic blasts). Each cell type is characterized by the
following cell properties:
• Proliferation rate, describing the frequency of cell
divisions per unit of time. In case of post-mitotic cells
the proliferation rate is considered equal to zero.
• Fraction of self-renewal (self-renewal rate),
describing the fraction of progeny cells returning to
the compartment occupied by the parent cells that
gave rise to them.
• Death rate, describing the fraction of cells dying per
unit of time. For simplicity, we assume that dividing
cells do not die and that non-dividing cells die at
constant rates.
We denote the compartment of dividing healthy cells as
c1 and that of mature cells as c2. We count the leukemic
clones starting from 1. The respective compartments of
the ith leukemic clone are denoted as li1 and li2 resp. The
proliferation rate of the healthy cells is denoted as pc and
that of the mitotic cells of the ith leukemic clone pil. The
respective fractions of self-renewal are denoted ac and
ail. Death rates of the non-dividing compartments are dc
and dli .
Feedback regulation of healthy hematopoiesis
Formation of healthy blood cells is subject to a tight regu-
lation, mediated by a system of lineage- and stage-specific
cytokines. If there is a need for more blood cells of a cer-
tain type, the concentration of cytokines increases and
stimulates formation of mature cells [17, 49]. For sim-
plicity, we consider only one feedback loop. We denote
s(t) the value of the feedback signal at time t. We set
s(t) = 11+kc2(t) , where k is a positive constant depend-
ing on production and elimination of cytokines [44]. This
expression can be derived from cytokine kinetics [44]. It
takes into account that the concentrations of important
cytokines such as EPO and G-CSF depend on the concen-
tration of mature cells [49]. The feedback signal assumes
values between 0 and 1.
On the basis of our earlier work and compatibility
with clinical data [44, 46], we assume feedback inhibi-
tion of the fraction of self-renewal by mature cells. The
fraction of self-renewal of the healthy cells is assumed
to be equal to ac(t) = aˆcs(t) and that of leukemic
cells of clone i to ail(t) = aˆils(t). The parameters aˆc
and aˆil can be interpreted as the maximal possible frac-
tion of self-renewal. Numerical solutions of the model of
hematopoiesis subject to this feedback were validated on
the basis of clinical observations and show good agree-
ment with patient data upon recovery from bone marrow
transplantation [46].
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Fig. 2 Overview of the mathematical model. aModel structure: The model includes one hematopoietic cell line and an arbitrary number of
leukemic clones. Leukemic and healthy cells interact by feedback signals. Due to mutations new clones with different properties arise. Mutation
rates of leukemic and healthy cells are denoted as ν and γ resp. b Example simulation: The panel shows the time course of mitotic leukemic cells.
The horizontal axis shows the time since appearance of the first leukemic cell. The simulation ends when the mature healthy cell count is below 5 %
of its steady state value. This corresponds to the death of the patient. Each color represents one clone
Model equations for the hematopoietic system
The flux to mitosis of healthy cells at time t equals pcc1(t).
During mitosis, a parent cell is replaced by two progeny
cells. The outflux from mitosis at time t equals 2pcc1(t),
of which the fraction 2aˆcs(t)pcc1(t) stays in compart-
ment 1 (process referred to as self-renewal). The fraction
2
(
1 − aˆcs(t)
)
pcc1(t) moves to compartment 2 (process
referred to as differentiation).
We obtain the following system of ordinary differential
equations
d
dt c1(t) =
(
2aˆcs(t) − 1
)
pcc1(t)
d
dt c2(t) = 2
(
1 − aˆcs(t)
)
pcc1(t) − dcc2(t)
s(t) = 11 + kc2(t)
with the initial conditions c1(0), c2(0) given.
Model of leukemia
We assume that healthy and leukemic cells respond
to the same feedback signals. This assumption is sup-
ported by the finding that leukemic cells express receptors
for hematopoietic cytokines [18] and that they interact
with the bone marrow microenvironment [20, 21]. Due
to cytokine clearance by receptor mediated endocytosis
[17, 49] leukemic cells contribute to the cytokine clear-
ance. In the presence of leukemic cells, the feedback signal
is given by
s(t) = 1
1 + kc2 + k ∑n(t)i=1 li2(t)
.
Here, n(t) denotes the number of leukemic clones
present at time t. This expression has been derived in
ref. [47] for the special case of one leukemic clone. The
proposed feedback mechanism has been validated based
on clinical data [23]. Model simulations suggest that the
choice of individual k values for each leukemic clones, i.e.,
modeling the signal as s(t) = 1
1+kc2+∑n(t)i=1 kili2(t)
has no sig-
nificant impact on the quantities considered in this study.
For n leukemic clones we obtain the following system of
equations:
d
dt c1(t) =
(
2aˆcs(t) − 1
)
pcc1(t)
d
dt c2(t) = 2
(
1 − aˆcs(t)
)
pcc1(t) − dcc2(t)
d
dt l
1
1(t) =
(
2aˆ1l s(t) − 1
)
p1l l11(t)
d
dt l
1
2(t) = 2
(
1 − aˆ1l s(t)
)
p1l l11(t) − d1l l12(t)
...
...
...
d
dt l
n
1(t) =
(
2aˆnl s(t) − 1
)
pnl ln1(t)
d
dt l
n
2(t) = 2
(
1 − aˆnl s(t)
)
pnl ln1(t) − dnl ln2(t)
s(t) = 1
1 + kc2(t) + k ∑ni=1 li2
with the initial conditions c1(0), . . . , ln2(0) given.
Mutations
We assume that mutations occur during genome replica-
tion which takes place beforemitosis.We consider the rate
to be identical for all clones and constant in time. This
is supported by the fact that genomic instability is a rela-
tively rare event in leukemias [15, 16]. The flux to mitosis
of leukemic clone i at time t is given as pilli1(t). We assume
that a fraction ν of the produced progeny has a mutation.
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Therefore, 2pilli1(t)ν mutated cells are produced at time t,
of which 2aˆils(t)pilli1(t)ν are in the mitotic compartment
and 2(1 − aˆils(t))pilli1(t)ν belong to the post-mitotic com-
partment. The influx of mutated mitotic cells from the
clone i is defined as αi(t) = 2aˆils(t)pilli1(t)ν. The number
of non-mutated cells is given by 2pilli1(t)(1 − ν), of which
2aˆils(t)pilli1(t)(1 − ν) are mitotic cells and the remainder,
2(1 − aˆils(t))pilli1(t)(1 − ν), belongs to the non-dividing
compartment. We obtain the following set of equations
describing dynamics of clone i:
d
dt l
i
1(t) = 2aˆils(t)pilli1(t)(1 − ν) − pilli1(t)
d
dt l
i
2(t) = 2(1 − aˆils(t))pilli1(t) − dilli2(t)
αi(t) = 2aˆils(t)pilli1(t)ν
A similar system of equations has been obtained in [40].
Since li2 is considered to be post-mitotic, we do not dis-
tinguish between cells that acquired a mutation during
the divisions and those that did not. The influx α(t) of
mutated mitotic cells of all leukemic clones at time t is
given by α(t) = ∑n(t)i=1 αi(t), where n(t) is the number of
leukemic clones present at time t.
We consider the rate α(t) as the rate of an inhomoge-
neous Poisson process. Poisson processes describe rare
events [50], therefore, they are a suitable framework to
describe mutations. We use the Poisson process to deter-
mine the time points of the mutations. At the respective
time points, one cell acquires a new mutation and gives
rise to a new clone. This founder cell is chosen from the
present clones according to their contribution αi to the
total rate α. Self-renewal and proliferation rates of the new
clone are chosen based on the parameters of the founder
cell. We assume that the traits (self-renewal and prolifera-
tion rates) of the new clone are normally distributed with
a predefined variance and the mean value correspond-
ing to the parameters of the founder cell. Since biological
parameters are restricted to a predefined interval, we use
truncated normal distributions. A suitable interval for
proliferation rates is between one division per year and
one division per day [46] and the fraction of self-renewal
is by definition between zero and one.
At the time of its birth a new clone consists of one
mitotic and zero post-mitotic cells. Due to the stochastic-
ity of cell fate decisions or due to cell death it is possible
that the new clone becomes extinct. For example, if the
newly generated mitotic cell divides and gives rise to
two differentiated progeny, the new clone will eventually
extinct, since there exist no more mitotic cells. We use the
theory of Galton-Watson processes to calculate the prob-
ability of extinction of new clones. We adopt the method-
ology from ref. [51], which is similar to the approach used
in ref. [31]. We notice that a clone eventually becomes
extinct if it has no mitotic cells. If a mitotic cell divides,
with the probability a2 both progeny aremitotic cells, with
the probability 2(1− a)a one progeny is a mitotic cell and
with probability (1 − a)2 both progeny are fully differen-
tiated. By a we denote the fraction of self-renewal of the
mitotic cells. The probability generating function for the
number of mitotic progeny is f (x) = a2x2 + 2a(1 − a)x +
(1 − a)2. If we assume in addition that the parent cell dies
with a probability d during division the probability gener-
ating function is f (x) = (1− d)(a2x2 + 2a(1− a)x+ (1−
a)2) + d.
If we assume that cells of the new clone divide at dis-
crete times iT, i ∈ N, where T is the average generation
time, we can use the theory of Galton-Watson processes
to calculate the extinction probability. We know that the
extinction probability is the smaller solution of f (x) = x
[28]. We neglect cell death and obtain for the extinction
probability
pe(a) = 2a
2 − 2a + 1
2a2 −
√(2a2 − 2a + 1
2a2
)2
− (1 − a)
2
a2 .
We notice that pe < 1 if a > 0.5. For each new
clone we calculate the extinction probability based on its
self-renewal rate at the time of emergence. With proba-
bility 1 − pe the new clone is introduced to the system
by adding two equations to the system describing dynam-
ics of mitotic and post-mitotic cells of the new clone.
With probability pe the new clone is not introduced to the
system since it becomes extinct.
According to biological data suggesting that all leukemic
cells are derived from one leukemic or preleukemic clone
[12], we neglect mutations in the healthy cells. Instead we
introduce one leukemic founder clone at t = 0 to the sys-
tem and study the dynamics of the founder clone and the
clones arising from it. Parameters of the founder clone are
assumed to be normally distributed with the means equal
to parameters of healthy hematopoietic cells.
Parametrization
The parameters of the hematopoietic system are adopted
from ref. [22]. In the following we shortly describe the cali-
bration. For details see ref. [22] and the references therein.
The numbers of myeloid mitotic (c¯1) and post-mitotic (c¯2)
cells and the neutrophil clearance (d2) are taken from liter-
ature. Analytical expressions of the steady state cell counts
allow to calculate pc based on c¯1, c¯2 and d2. The parameter
k can be expressed as a function of known quantities and
aˆc. To obtain an appropriate value for aˆc, we simulate stem
cell transplantation.We know that after transplantation of
a dose of 3 to 5 · 106 cells per kg body weight, patients
recover to 5 · 108 neutrophils per liter of blood within 15
days. To set the initial condition we assume that the ratio
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of myeloid to erythroid cells in the transplant is as in the
healthy marrow between 2:1 and 4:1. We choose a1 such
that we observe recovery after 2-3 weeks. This results in
the following parameters: aˆc = 0.87, pc = 0.45/day, dc =
2.3/day, k = 1.85 · 10−9, dl = 0.5/day. These parameters
refer to healthy cells. Parameters of the leukemic cells are
chosen randomly according to normal distributions.
For the simulations the rate ν is varied between 5 · 10−8
and 10−11. Standard deviations for the normal distribu-
tions are varied between 0.001 and 0.1. The standard
deviations and mutation rates used to obtain the figures
are specified in the figure captions. Stopping criteria for
simulations are either decline of healthy blood cells to less
than 5 % of the healthy steady state value or a simulated
time span that exceeds 100 years of age for a given patient.
An example simulation is depicted in Fig. 2b.
Results
Simulations over wide parameter ranges, including varia-
tion of mutation rates over several orders of magnitude,
show that the phenomena presented below are robust with
respect to the parameter choice.
Self-renewal rate of significant clones increases during the
course of the disease
We first ask how cell properties evolve during the course
of the disease. For this purpose, we compare self-renewal
and proliferation rates of the significant clones of 600 sim-
ulated patients. The significant clones emerge at different
time points due to mutations. We count the significant
clones in the order of the time of their emergence. Simu-
lation results imply that in more than 95 % of patients the
self-renewal rate of the second emerging significant clone
is larger than the self-renewal rate of the first emerging
significant clone. The self-renewal rate of the third sig-
nificant clone is larger than the self-renewal rate of the
second significant clone and so forth. Interestingly, prolif-
eration rates do not differ significantly among significant
clones. This finding confirms that high self-renewal rate
is beneficial for expansion of clones. Previous simulation
studies have shown that high self-renewal rate might be
related to poor prognosis and high resistance to ther-
apy [22, 23]. Simulation results imply that clones become
more aggressive during the course of the disease. In the
remaining 5 % of simulated patients, the following phe-
nomena have been observed: (i) in very rare cases (less
than 1 %) a slight reduction in the self-renewal rate is
compensated by an increase in proliferation rate, (ii) two
new clones emerge within a short time span, the self-
renewal rate of both clones is larger than the self-renewal
rate of the parent clones, but one of the emerging clones
has a slightly reduced self-renewal rate compared to the
other. In this case both new clones have growth advan-
tage at the time of their origin and, therefore, grow to
a significant size. The increasing self-renewal of clones
over time is the result of a selection process. The selec-
tion was studied numerically in [22] and proved in [52]
for a multi-clonal system in absence of mutations. When
a new clone arises due to a mutation, its self-renewal and
proliferation rates can be larger or smaller than the cor-
responding rates of the parent clone. They are chosen
according to normal distributions with constant stan-
dard deviation and means equal to the parameter values
of the parent clone. It is not straightforward to predict
whether progeny clones with higher self-renewal, higher
proliferation or both have more competitive advantages.
Simulation results show that among the newly arising
clones with random proliferation and self-renewal values
those with high self-renewal are more competitive than
those with high proliferation. The results are depicted in
Fig. 3.
Properties of the first clone determine if there is no
outbreak of the disease, a monoclonal disease, or clonal
diversity
The number of significant clones varies among the
patients [12]. We compared self-renewal and prolifera-
tion rates of the significant clones in simulated patients
to investigate how these properties impact the total num-
ber of significant clones per patient. As mentioned above,
we suppose that all leukemic clones originate from a sin-
gle founder clone which itself is derived from healthy
hematopoietic cells. Simulation results imply that the self-
renewal rate of the founder clone has a major impact on
the total number of significant clones emerging during
the course of the disease. If the founder clone has a high
self-renewal rate it has the ability to expand fast. This
fast expansion leads to a clinical disease and potential
death of the patient before additional significant clones
can emerge. In case of very small self-renewal rate, the
founder clone expands slowly and the disease does not
become significant throughout the life span. In case of
intermediate self-renewal rate of the founder clone, multi-
ple significant clones arise. If the founder clone gives rise
to a clone that grows to a significant size over time, the
self-renewal rate of this second significant clone deter-
mines whether a third significant clone will arise. If the
self-renewal rate of the second significant clone is high,
fast expansion and progression of the disease follow. The
remaining life time of the patient is too short for emer-
gence of additional significant clones. If the self-renewal
rate of the second significant clone has intermediate val-
ues, disease progression is slow and more significant
clones can emerge. This principle is extended to a higher
number of leukemic clones: If the self-renewal rate of
the first n significant clones is intermediate, the proba-
bility is high that additional clones will emerge. If one
clone among the first n significant clones has a high
Stiehl et al. Biology Direct  (2016) 11:51 Page 7 of 19
Fig. 3 Self-renewal rate of significant clones increases during the course of the disease. The figure is based on 600 simulated patients. a Time
evolution of one simulated patient who developed 4 clones during the course of the disease. The first, second, third and fourth significant clone are
depicted using different colors. b Self-renewal rates of the first, second, third and fourth significant leukemic clone of the subgroup of patients
harboring 4 significant clones at the end of the simulation (reduction of healthy cell count by 95 %). The self-renewal rates differ significantly
(p < 0.05 in t-test) between first and second, second and third, third and fourth clone. c Self-renewal rates of the first, second and third significant
leukemic clone of the subgroup of patients harboring 3 clones at the end of simulations. The self-renewal rates differ significantly between the
clones (p < 0.05 in t-test). d Proliferation rates of the first, second and third significant leukemic clone of the subgroup of patients harboring 3
clones at the end of simulation. The proliferation rates do not differ significantly between the clones (p > 0.05 in t-test). Parameters: mutation rate
ν = 5 · 10−9, self-renewal and proliferation rates of the new clones are normally distributed with the means of the distributions equal to
proliferation and self-renewal rates of the parent clone and standard deviation equal to 0.005. The central mark is the median, the edges of the box
are the 25th and 75th percentiles, points are drawn as outliers if they are larger than q3 + 1.5(q3 − q1) or smaller than q1 − 1.5(q3 − q1), where q1
and q3 are the 25th and 75th percentiles, respectively
self-renewal rate, progression is fast and no more clones
emerge. Clones with small self-renewal rate never grow
to a significant size. Proliferation rates of the clones do
not have a significant impact on the total number of
clones. Simulations show that if we restrict self-renewal
rate of the leukemic founder clone to intermediate val-
ues, e.g., between 0.872 and 0.875, the number of clones
per patient increases. The results are summarized in
Fig. 4.
Self-renewal rate increases with an increasing depth of
clones
In leukemia patients, clonal hierarchies show considerable
interindividual variations [12]. We ask how the proper-
ties of clones influence the depth of the clonal hierarchy.
We assume that the founder clone has depth 1. Clones
that have acquired k additional mutations in compari-
son to the founder clone have depth 1 + k. Depth of a
clonal hierarchy is understood as the maximal depth of its
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Fig. 4 Impact of self-renewal rate on the total number of significant clones. Data from 600 simulated patients. a Overview over panels (b)–(d). bWe
compare self-renewal rate of the first significant clone in two patient groups. Group 1: patients harboring only one significant clone throughout the
disease. Group 2: patients harboring more than one significant clone. The self-renewal rate of the first significant clone is significantly higher in
group 1. Leftmost plot in (b): If the self-renewal rate of leukemic clones is close to the self-renewal rate of healthy cells, no significant clones emerge.
cWe compare the self-renewal rate of the second significant clone in two patient groups. Group 1: patients harboring two significant clones
throughout the disease. Group 2: patients harboring more than two significant clones. The self-renewal rate of the second significant clone is
significantly higher in group 1. dWe compare the self-renewal rates of the third emerging significant clone in two patient groups. Group 1: patients
harboring three significant clones throughout the disease. Group 2: patients harboring more than three significant clones. The self-renewal rate of
the third significant clone is significantly higher in group 1. e Explanation of data in (b)–(d): Clones with high self-renewal rates lead to fast
progression of the disease and death before new significant clones can emerge. Clones with small self-renewal rates never grow to a significant size.
Clones with intermediate self-renewal rates grow with moderate speed and their offspring have enough time to grow to a significant size.
Proliferation rates do not differ significantly between all considered groups. Parameters: mutation rate ν = 5 · 10−9, self-renewal and proliferation
rates of the new clones are normally distributed with the mean of the distributions equal to proliferation and self-renewal rates of the parent clone
and standard deviation equal to 0.005. Significance: p < 0.05 in t-test
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clones. Simulations indicate that the self-renewal rate of
the clones increases with their depths. This is plausible:
To be able to give rise to new clones, a given clone has
to achieve a critical mass of cells. Only then it is proba-
ble that cells of this clone mutate and give rise to offspring
clones. To achieve the critical mass, a clone needs prop-
erties favorable for efficient expansion. This occurs if and
only if its self-renewal rate is increased compared to its
mother clone, since otherwise the mother clone outgrows
its offspring.
Simulations show that a deep clonal hierarchy requires
a step-wise increase of self-renewal rate with each
mutation. The step size determines how deep the
hierarchy will be. If the step size is too small, offspring
clones grow slowly and it takes long time until they and
their offspring grow to a significant size. In this case the
parent clone remains dominant in size and is responsible
for disease progression. If the step size is large, the off-
spring clones grow fast and the patient dies before poten-
tial new offspring achieve a significant size. In both cases
the hierarchy is flat. Only if self-renewal rate increases by
steps of intermediate size, deep hierarchies are observed.
In this case, the offspring clones have a sufficient growth
advantage compared to their parents but they grow slow
enough for their offspring to achieve a significant size and
to give rise to new clones.
Self-renewal rate of the significant clone which appears
first has a major impact on the depth of the hierarchy.
If it has a high self-renewal rate, the disease progresses
fast and the patient dies before offspring achieve a critical
mass. In case of small self-renewal rate of the first clone,
deep hierarchies can emerge, supposed that it gives rise
to offspring with higher self-renewal rates. Analogously
the properties of a clone of depth 2 determine whether a
clone of depth 3 can emerge. The proliferation rate has no
impact on the depth of the hierarchy.
High self-renewal rate is potentially linked to poor prog-
nosis and fast progression of the disease [22, 23]. If we
consider the maximum of self-renewal capacity over all
significant clones, the simulations imply that it increases
significantly with the depth of the clonal hierarchy. There-
fore, our study suggests that the depth of the clonal
hierarchy could be considered a prognostic parameter.
Since in our simulations deep hierarchies are linked to
high self-renewal rates, our results suggest that deep hier-
archies could be linked to poor prognosis. Interestingly,
there is no correlation between the total number of sig-
nificant clones and the maximal self-renewal rates of the
significant clones. The results are summarized in Fig. 5.
Cooperativity of mutations might explain emergence of
deep hierarchies
In the patients investigated in ref. [12], hierarchies of
depths between 3 and 5 have been detected. Due to the
findings described in the previous paragraph, emergence
of such hierarchies requires a coordinated increase of the
self-renewal rate with each acquired mutation. Appear-
ance of clones with too high self-renewal rates leads to
fast progression and death before deep hierarchies can
be established. Therefore, the existence of deep hierar-
chies is not compatible with mutations that lead to large
changes of cell properties. Indeed, if we assume that traits
of mutated clones are uniformly distributed in the trait
space, deep hierarchies are never observed in simulations.
This observation raises the question which probabil-
ity distributions are suitable choices to model the effect
of mutation in the trait space. We have investigated the
assumption that the traits of the new clone follow nor-
mal distributions with means equal to the traits of the
cell that gave rise to the new clone. Depending on the
assumed standard deviations of the normal distributions
we can observe hierarchies of varying depths. If the stan-
dard deviations are too large, the hierarchies remain flat,
since aggressive clones that lead to fast progression and
death emerge early in the disease. If the standard devia-
tions are too small, the traits of the offspring clones are
very close to the traits of the parent clones. Therefore, the
offspring clones have little growth advantage compared to
their parent clones and consequently need long time to
grow to a significant size and to produce offspring growing
to a significant size. In these cases the hierarchy of signif-
icant clones remains flat. Only if the standard deviation is
within a limited range, a considerable number of patients
with deep hierarchies is observed in the simulations. In
acute leukemias, where genetic instability is rare, gener-
ation of large numbers of mutated cells and selection of
those which exactly fit the properties required to establish
deep hierarchies is not a realistic scenario, since muta-
tion rates are relatively low, compared to other cancers.
Leukemias show high interindividual genetic variability.
The assumption that all described mutations will lead to
exactly those changes in the self-renewal rates that are
required to establish deep hierarchies seems also improb-
able.
If we assume that the standard deviation of the normal
distribution according to which the traits of the offspring
are chosen increases with each mutation, deep hierarchies
become a more frequent event. This is plausible since
small standard deviations for the first mutation avoid
emergence of clones that show fast expansion and sub-
sequent death of the patient. Step-wise increase of stan-
dard deviation with each mutation allows the offspring to
gain sufficient growth advantage compared to the parent
clones that they can grow to a significant size. At the same
time large jumps leading to aggressive clones remain rare.
The assumption that jump sizes in the trait space
increase with the number of mutated genes in a cell seems
plausible from a biological point of view. Cells are known
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Fig. 5 Impact of the self-renewal rate on the depth of the hierarchy. The figure is based on 600 simulated patients. a Examples for hierarchies of
different depths. Colors are used to visualize clones of different depths. b Self-renewal rate of significant clones increases significantly (p < 0.05 in
t-test) with the depth of the clones in hierarchies. Considered are only patients with clonal hierarchies of depth 3. c Properties of the first clone in
the hierarchy decides about the depth of the hierarchy. Only if self-renewal rate of the first clone is small enough deep hierarchies emerge. If
self-renewal rate of the first clone is high, disease progression and death occur before deep hierarchies can establish. d Comparison of self-renewal
rates of significant and insignificant clones of depth 2. Self-renewal rates of insignificant clones is significantly smaller than self-renewal rates of
significant clones. This demonstrates that clones do not become significant if their self-renewal rate is too small. Some of the insignificant clones
show high self-renewal rates. These clones have originated late during the disease and could not grow to a significant size before death of the
patients. If proliferation rate is very slow, clones with high self-renewal cannot grow to a significant size. Proliferation rate has no impact on the
depth of the hierarchy. Parameters: mutation rate ν = 5 · 10−9, self-renewal and proliferation rates of the new clones are normally distributed with
the mean of the distributions equal to proliferation and self-renewal rates of the parent clone and standard deviation equal to 0.005
to have redundant pathways for regulation of important
functions. Perturbation of one pathway by a mutation
might therefore lead to only small jumps in the trait space,
whereas subsequent perturbation of multiple pathways
may lead to larger jumps in the trait space. This means
that the presence of a mutation facilitates the occurrence
of large effects due to an additional mutation. In this sense
the different mutations are cooperative.
The importance of cooperativity is underlined by the
following simulation experiment: We assume that the
probability of large jumps in the trait space increases with
the number of accumulated mutations. We model these
effect using normal distributions with increasing standard
deviations σ1 < σ2 < σ3 . . ., i.e., the size of the jump
in the trait space due to the first mutation is given by a
normal distribution with standard deviation σ1, the jump
due to the second mutation by a normal distribution with
standard deviation σ2 etc. We simulate the emergence of
clonal hierarchies under these assumptions. We repeat
simulations under modified assumptions, for example, we
Stiehl et al. Biology Direct  (2016) 11:51 Page 11 of 19
assume that for all mutations the size of the jump in the
trait space is given by a normal distribution with stan-
dard deviation equal to σ1 or equal to σ2 etc. We run
simulations for all possible permutations of σ1, σ2, σ3 . . ..
Comparison of simulation results shows that the num-
ber of patients harboring hierarchies of depth 4 or more
is maximized if standard deviations increase from one
mutation to another. The results are depicted in Fig. 6.
Impact of the mutation rates and probability distributions
on the clonal hierarchies
We studied the architecture of clonal hierarchies for sev-
eral mutation rates. For increased mutation rates the total
number of clones increases. Interestingly, the number of
significant clones increases only moderately if the muta-
tion rates are varied over several orders of magnitude; for
example, if the rate increases from 5 · 10−10 to 5 · 10−9,
the mean number of all clones increases by a factor of 8,
whereas the mean number of significant clones increases
only by 1. In all cases the number of significant clones was
smaller than 15 and for 80 % of the patients smaller than
10. This is in line with the observation of clone numbers
in experimental studies [11, 12]. This finding underlines
the role of competition between the different clones. The
competition selects among an increasing total number of
clones always a small number of significant clones.
Simulation results imply that patients with less aggres-
sive clones and without disease outbreak are over-
represented in case of small mutation rates. Patients with
highly aggressive clones and fast disease progression are
over-represented in case of high mutation rates. This is
plausible: The higher the mutation rate, the more clones
are generated per unit of time. The probability that at
least one clone per patient has favorable growth properties
increases with the number of generated clones. Similarly
the probability that highly aggressive clones and fast dis-
ease progression occur increases with increasingmutation
rate. For all mutation rates we observed that clonal hierar-
chies are flat in case of fast disease progression and in case
of very slow disease progression compared to cases with
intermediate disease progression.
Increased mutation rates act in favor of deep hierar-
chies. Nevertheless this effect is mild and the mean depth
increases by 1 if the mutation rate increases by a factor of
Fig. 6 Impact of cooperativity between mutations on depth of the hierarchy. The figure is based on 100 simulated patients. The number of patients
harboring a clonal hierarchy of depth 4 or more is maximized, if the jumps in the trait spaces increase with the number of mutations. Parameters:
Self-renewal and proliferation rates of the leukemic founder clone are drawn from normal distributions with mean values equal to proliferation and
self-renewal rates of healthy cells and standard deviation σ1 = 0.0014. First mutation: self-renewal and proliferation rates of the new clone are
normally distributed with the means of the distributions equal to proliferation and self-renewal rates of the founder clone and standard deviation
σ2 = 5 · σ1. Second mutation: self-renewal and proliferation rates of the new clone are normally distributed with the means of the distributions
equal to proliferation and self-renewal rates of the parent clone and standard deviation σ3 = 20 · σ1. Third and higher mutations: self-renewal and
proliferation rates of the new clone are normally distributed with the means of the distributions equal to proliferation and self-renewal rates of the
parent clone and standard deviation σ3 = 100 · σ1. Mutation rate ν = 5 · 10−9
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10. This observation can be explained by the fact that high
mutation rates lead to increased numbers of leukemic
clones. Therefore, the probability that a clone gives rise
to at least one offspring with favorable growth properties
increases. As discussed above, probability distributions
according to which the traits of new clones are determined
have an important effect on the depth of the hierarchy. If
uniform distributions over the possible parameter range
are chosen, deep hierarchies are very rarely observed.
Also the total number of significant clones is decreased.
Similarly, if standard deviations of normal distributions
increase over a certain threshold, the mean number of
significant clones slightly decreases, e.g., the number of
significant clones decreases by 1 if the standard deviations
are increased from 0.01 to 0.05.
Comparison to data
We compare the structure of the clonal hierarchy obtained
by simulations of our model with the clonal hierarchies
in 30 patients from [12]. The patients’ data are based on
genetic studies. To take into account the limitations of
the experimental methods, we compare the data only to
significant clones observed in the numerical simulations.
For more than 60 % of the patients the clonal hierarchies
are reproduced by our model. Besides, we observe both
hierarchies obtained in numerical simulations that are not
found in the patients’ data and hierarchies in the data
which could not be reproduced numerically. The latter
could be explained by dynamic variation over the hier-
archies in time. The hierarchy at diagnosis only reflects
the situation at one time point. In simulation results we
only considered the hierarchies at three time points per
patient, namely at the time points whenmature cell counts
have decreased by 5, 50 and 95 %. In approximately 30 % of
the patients with hierarchies not reproduced by the sim-
ulations, patient data could be reproduced if one clone
existing in the simulations with an insignificant size would
grow to a significant size. Examples are provided in Fig. 7.
Discussion
Wepropose amathematical model to study the emergence
of clonal heterogeneity in acute leukemias. The model
considers the interactions of multiple leukemic clones
with healthy hematopoiesis and the emergence of new
clones due to mutations. We use computer simulations to
study the impact of leukemic cell self-renewal and pro-
liferation rates on the structure of the clonal hierarchy.
At the same time, the model provides insights into how
the properties of clones at different positions in the clonal
hierarchy differ. These questions are clinically relevant,
since the patients’ prognosis and the treatment response
may depend on the properties of the leukemic cells [23].
Model simulations suggest that the self-renewal rate of
leukemic clones has a major impact on the structure of the
clonal hierarchy, whereas proliferation rates show no sig-
nificant influence. The self-renewal rate of the emerging
clones increases during the course of the disease. There
is evidence that a high self-renewal rate of clones may be
linked to poor prognosis [23]. In this sense, clones appear-
ing later during the disease are more aggressive than those
present at the beginning of the disease. Similarly, simula-
tions suggest that the self-renewal rates of clones increase
with increasing depth of the hierarchy, whereas prolifer-
ation rates do not depend significantly on the depth of
clones in the hierarchy. Simulations of large patient groups
suggest that there might exist a significant relationship
between the depth of the clonal hierarchy and the max-
imal self-renewal rate. This finding suggests to evaluate
the depth of the clonal hierarchy as a potential marker for
patient prognosis.
Mutations detected in acute leukemias act at differ-
ent regulatory levels. There is evidence that many of
them lead to increased self-renewal. Important exam-
ples for genes where mutations lead to increased self-
renewal are the chromatinmodifiersTET2 [53],DNMT3A
[54] and MLL [55] or the transcription factors C/EBPα
[56], RUNX1/CBFβ [57, 58] and factors encoded by the
HOX genes, e.g., as NUP98-HOXA9 [59]. Other exam-
ples include the isocitrate dehydrogenase IDH1 [60], the
NRAS gene [61] or the multi-functional protein NPM1
[62]. Importantly, more than one of these mutations can
occur in the same cell [63, 64]. This is in line with the
step-wise increase in self-renewal observed in the model
simulations.
Emergence of the clonal hierarchy is a dynamic process.
Model simulations show that the properties of the exist-
ing clones have an impact on the structure of the clonal
hierarchy in the future. Presence of aggressive clones with
high self-renewal rates leads to fast progression of the dis-
ease. The short remaining lifespan of the patient limits the
number of new clones that can emerge and grow to a sig-
nificant size. Therefore in presence of aggressive clones,
the clonal hierarchies consist of a relatively small number
of clones. On the other hand, if the self-renewal rates of
new clones is very close to the self-renewal rate of the par-
ent clone, the new clone expands slowly and takes a long
time to reach a significant size. Therefore, mutations caus-
ing only small changes in self-renewal rates also lead to
small numbers of significant clones and flat hierarchies.
The model simulations suggest that the emergence of
deep clonal hierarchies is a complex process. To give rise
to offspring, a clone requires a critical mass, otherwise it
is unlikely that a clone acquires new mutations. A deep
hierarchy is created if new clones have high enough self-
renewal rates to grow to a critical mass before the patient
dies, but not too high self-renewal rates to avoid fast
progression and death before the new clones can pro-
duce their own offspring. Simulations imply that these
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Fig. 7 Examples for the clonal architecture detected in leukemic patients and simulations. Each tree corresponds to one patient. a Clonal hierarchies
detected in patients from [12] and in simulations. b Clonal hierarchies detected in simulations but not in patients from [12]. c Clonal hierarchies
detected in patients from [12] but not in simulations. The reconstruction of the clonal architecture from genetic measurements is not always
unique. In case of ambiguity only one possibility is shown in the figure. Parameters were set as specified in the caption of Fig. 6
constraints are rarely met if one assumes that differ-
ent mutations act independently, i.e., the properties of
a new clone compared to the parent clone follow the
same random distribution for each mutation. This lim-
itation can be overcome if cooperativity of mutations
is assumed, i.e., if the probability that a new muta-
tion leads to large changes of cell properties increases
with the number of mutations that the cell has experi-
enced in the past. Since deep hierarchies are frequently
observed in patients (ref. [12]) it seems very plausi-
ble that cooperativity of mutations plays a role during
evolution of the acute leukemias. In the presence of coop-
erativity we observe a significant increase in the emer-
gence of deep hierarchies and also in the interindividual
heterogeneity of clonal hierarchies. Assuming cooper-
ativity allows to reproduce many of the clonal hier-
archies detected in patients from ref. [12] by model
simulations.
Computer simulations of the proposed model suggest
that increasing mutation rates have only a limited impact
on the number of significant clones. Although the total
number of clones increases with increasing mutation
rates, the number of significant clones remains approxi-
mately constant. This observation can be explained by the
strong competition among leukemic clones. This is in line
with experimental studies [11, 12] which report similar
numbers of clones in different patients.
Genetic and epigenetic mechanisms are closely inter-
twined in leukemogenesis. Genes involved in epigenetic
encoding are often mutated in leukemias [65, 66]. In addi-
tion, epigenetic changes can be driven bymutations which
are not directly linked to the epigenetic machinery such as
IDH1/2 or several transcription factors [67]. In principle,
epigenetic mechanisms can be included in the proposed
modeling framework. It has to be clarified whether epige-
netic effects can be modeled similar to mutations as ran-
dom, independent, discrete jumps in the trait space. This
may be true for epigenetic changes that mimic genetic
mutations such as in the case of DNMT3A [68]. In other
cases it might be more appropriate to model epigenetic
modifications as drift or diffusion in a continuous trait
space as done in [33]. Plasticity and potential reversibility
are important hallmarks of epigenetic changes. The possi-
bility that clones readopt the traits of their ancestors can
be included easily into the model. The same holds for the
potentially different time scales of genetic and epigenetic
modifications.
Mathematical modeling of clonal hierarchies can be a
helpful tool, since it allows to link cell properties to a
position in the clonal hierarchy. This may have a clin-
ical relevance. Model simulations imply that the clonal
hierarchy allows drawing conclusions about the course of
the disease, even if the latter is known only at one time
point. This work has the following clinical implications
Stiehl et al. Biology Direct  (2016) 11:51 Page 14 of 19
which could be discussed and evaluated in clinical trials:
(i) A small number of clones detected at diagnosis may
argue in favor of a rapidly progressing disease with aggres-
sive clones. These patients may have poor prognosis and
potentially a rapid progression after standard treatment
or a poor treatment response. (ii) Deep hierarchies e.g., of
order 5 or more, may argue for a long course of the dis-
ease before diagnosis. The probability for the presence of
aggressive clones is high, which may limit prognosis. Nev-
ertheless clones at the top of the hierarchy may respond
to the treatment. (iii) Hierarchies of intermediate depth,
e.g., 3 or 4 may argue in favor of long courses and limited
aggressiveness of the clones. Patients with good prognosis
may be over-represented in this group.
Conclusion
Emergence of heterogeneity in acute leukemias is a com-
plex process. Multi-clonality and deep hierarchies emerge
only from leukemic clones with intermediate self-renewal.
Emergence of deep hierarchies is facilitated by a coop-
erativity of different mutations. There is no correlation
between the position of a clone within the hierarchy and
its proliferation rate. Self-renewal rates of leukemic clones
increase with the depth of mutation hierarchy. Therefore,
the structure of the hierarchy may serve as a marker for
patient prognosis.
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has to be clarified whether epigenetic effects can be mod-
eled similar to mutations as random, independent, discrete
jumps in the trait space. This may be true for epigenetic
changes that mimic genetic mutations such as in the case
of DNMT3A [68]. In other cases it might be more appropri-
ate to model epigenetic modifications as drift or diffusion
in a continuous trait space as done in [33]. Plasticity and
potential reversibility are important hallmarks of epige-
netic changes. The possibility that clones readopt the traits
of their ancestors can be included easily into the model.
The same holds for the potentially different time scales of
genetic and epigenetic modifications.
Reviewer’s report 3: Tomasz Lipniacki, Institute of
Fundamental Technological Research, Polish Academy of
Sciences,Warsaw, Poland
Reviewer summary:
Thomas Stiehl et al. propose a simple model of
hematopoiesis of healthy and leukemic cell populations.
The novelty is in inclusion of mutations that lead to time
varying number of leukemic clones. The aim is to link the
number of mutations that characterize a given clone with
the self-renewal rate (fraction of divisions that do not lead
to differentiation). Overall this is a nice study worth pub-
lishing, however some aspects require some clarification
or more direct formulation.
Reviewer recommendations to authors:
1. The authors found that the self-renewal rate depend of
the depth of clone in the hierarchy. It is not clear whether
it is a simple consequence of assumption that clones pass
self-renewal rate to the new clone emerging due to muta-
tion. If so the clones with higher self-renewal rate that
are more abundant have higher chance to give rise to new
clones, and these clones will be characterized with higher
self-renewal rate. The Authors write that traits of the new
clone are normally or uniformly distributed (page 7), but
no details are given.
Authors’ Response: The increasing self-renewal of clones
is the result of a selection process. We added an explana-
tory paragraph to the Results section (p. 9, lines 200–33):
The increasing self-renewal of clones over time is the result
of a selection process. The selection was studied numeri-
cally in [22] and proved in [52] for a multi-clonal system
in absence of mutations. When a new clone arises due to
a mutation, its self-renewal and proliferation rates can be
larger or smaller than the corresponding rates of the parent
clone. They are chosen according to normal distributions
with constant standard deviation and means equal to the
parameter values of the parent clone. It is not straight-
forward to predict whether progeny clones with higher
self-renewal, higher proliferation or both have more com-
petitive advantages. Simulation results show that among
the newly arising clones with random proliferation and
self-renewal values those with high self-renewal are more
competitive than those with high proliferation. We have
clarified the choice of parameters for the new clones in the
“Methods” section:
• Page 7, lines 15–19: We assume that the traits
(self-renewal and proliferation rates) of the new clone
are normally distributed with a predefined variance
and the mean value corresponding to the parameters
of the founder cell.
• Page 8, lines 37–39: Standard deviations for the
normal distributions are varied between 0.001 and 0.1.
The standard deviations and mutation rates used to
obtain the figures are specified in the figure captions.
2. In “Parametrization” subsection Authors write that
ac = 0.87 (I think that authors mean aˆc since ac depends
to the strength of the negative feedback i.e. number
of cells), then they write that for Fig. 4 self-renewal is
between 0.872 and 0.875?
Authors’ Response:We corrected the notation. The max-
imal self-renewal of 0.87 refers to the self-renewal of
healthy cells. We have clearly indicated this in the revised
version. The range of self-renewal between 0.872 and 0.875
refers to self-renewal of leukemic cells. We added the fol-
lowing sentences:
• Page 8, lines 31–33: aˆc = 0.87, pc = 0.45/day,
dc = 2.3/day, k = 1.85 · 10−9, dl = 0.5/day. These
parameters refer to healthy cells. Parameters of the
leukemic cells are chosen randomly according to
normal distributions
• Page 10, line 12: Simulations show that if we restrict
self-renewal rate of the leukemic founder clone to
intermediate values, e.g., between 0.872 and 0.875,
the number of clones per patient increases.
3. It is not clear how long are the simulations? When
self-renewal rate multiplied by feedback strength s(t) is
larger than 1/2, the cell sub-populations are growing. It
is not clear whether the authors run the simulations long
enough to reach the constant population size limit. A
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figure showing number of cells in each clone would be
helpful.
Authors’ Response:We added a panel showing an exam-
ple for the time course of the leukemic clones to Fig. 2. As
shown in [22, 52], the cell count in each clone converges
asymptotically to an equilibrium, which is nonzero only
in the case of clones with maximal fitness, i.e., the largest
self-renewal. In clinical scenarios, patients die before the
equilibrium is reached. Allowing mutations with increas-
ing self-renewal not approaching one would lead to a
dynamics that does not converge to an equilibrium. The
latter is however an artificial example as far as biological
applications are concerned.
4. Since the clone starts from single founder cell, in the
beginning of each clone ODE formalism is not adequate –
some comment is needed here.
Authors’ Response: Following the advice of Reviewer 1
(point 3.) we extended the model to take into account
extinction probabilities of newly generated clones. For each
new clone we calculate the extinction probability based
on the theory of Galton-Watson Processes. The probability
that a new clone is introduced to the system is equal to its
probability of non-extinction.
5. The conclusion in abstract that “clonal heterogeneity
might impact the course of the disease” is very vogue.
Authors’ Response: We have replaced this formulation
by a more specific statement: Comparison of patient data
and simulation results suggests that the self-renewal of
leukemic clones increases with the emergence of clonal
heterogeneity.
6. Technical: Page 5 “Model equations for hematopoietic
system” there is once pc once pc – I think it denotes the
same thing.
Authors’ Response: Thank you. We corrected it.
Abbreviation
Resp.: Respectively
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